Clarity Pharmaceuticals Ltd
Clarity Pharma Secures Key Supply Deal to Boost Commercialisation of Prostate Cancer Agent
Clarity Pharmaceuticals inks Theragenics Cu-64 deal to scale US manufacturing for 64Cu-SAR-bisPSMA ahead of FDA NDA, boosting commercialization.
Clarity Pharmaceuticals signs copper-64 isotope supply deal for use in prostate cancer trials
Clarity Pharmaceuticals (ASX: CU6) has signed a deal with the Australian Institute for Bioengineering and Nanotechnology (AIBN), located within the University of Queensland, for the supply of the copper-64 (cu-64) isotope used in the manufacture of diagnostic 64Cu-SAR-bisPSMA. Clarity will use the isotope to support the Phase III Clarify and Amplify registrational trials, an ongoing […]
Clarity Pharmaceuticals gains FDA fast-track status for advanced prostate cancer imaging drug
Oncology specialist Clarity Pharmaceuticals (ASX: CU6) has been granted fast-track designation by the US Food and Drug Administration (FDA) for the use of its 64Cu-SAR-bisPSMA in positron emission tomography imaging for prostate cancer. SAR-bisPSMA – a next-generation theranostic radiopharmaceutical with dual prostate-specific membrane antigen (PSMA)-targeting agents linked to Clarity’s SAR chelator technology – utilises copper […]
Clarity Pharmaceuticals begins phase II trial using SAR-Bombesin as prostate cancer diagnostic
Clarity Pharmaceuticals (ASX: CU6) has begun a phase II diagnostic trial for patients with prostate cancer using its Copper-64 SAR-Bombesin product in imaging scans. According to Clarity, SAR-Bombesin is a “highly targeted” wide-ranging cancer radiopharmaceutical. It has “broad cancer application” and works by targeting the gastrin-releasing peptide receptor (GRPr), which is present in a range […]